• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Physical activity and exercise motivation of multiple myeloma patients: a prospective cross-sectional study

by | Jul 3, 2024 | Publications

Oncologist. 2024 Jul 2:oyae111. doi: 10.1093/oncolo/oyae111. Online ahead of print. ABSTRACT BACKGROUND: Multiple myeloma (MM) is the second most common hematological malignancy with its prevalence increasing. Patients with symptomatic MM can show numerous...

Central nervous system multiple myeloma: A real-world multi-institutional study of the Greek Myeloma Study Group

by | Jul 2, 2024 | Publications

Am J Hematol. 2024 Jul 2. doi: 10.1002/ajh.27425. Online ahead of print. ABSTRACT Central nervous system (CNS) involvement is a rare and aggressive complication of multiple myeloma (MM). We identified 54/4352 MM patients (1.2%), who developed CNS-MM between 2000 and...

The role of immune checkpoint inhibitors: Variable number of tandem repeat (VNTR) polymorphism in the second exon of the P-selectin glycoprotein ligand-1 (PSGL-1) gene polymorphism in multiple myeloma

by | Jul 2, 2024 | Publications

Mol Carcinog. 2024 Jul 2. doi: 10.1002/mc.23787. Online ahead of print. ABSTRACT Somatic mutations and polymorphisms may play a role in multiple myeloma (MM) susceptibility and survival. One of the immune checkpoint inhibitors is P-selectin glycoprotein ligand-1...

The impact of continuous lenalidomide maintenance treatment on people living with multiple myeloma-a single-centre, qualitative service evaluation study

by | Jul 2, 2024 | Publications

Support Care Cancer. 2024 Jul 2;32(7):479. doi: 10.1007/s00520-024-08663-4. ABSTRACT PURPOSE: Continuous lenalidomide maintenance treatment after autologous stem cell transplantation delivers improvement in progression free and overall survival among newly diagnosed...

Comprehensive analysis of microRNAs modulated by histone deacetylase inhibitors identifies microRNA-7-5p with anti-myeloma effect

by | Jul 2, 2024 | Publications

Int J Hematol. 2024 Jul 2. doi: 10.1007/s12185-024-03812-1. Online ahead of print. ABSTRACT Basic research to expand treatment options for multiple myeloma is greatly needed due to the refractory nature of the disease. Histone deacetylase (HDAC) inhibitors, which are...

LILRB4 on multiple myeloma cells promotes bone lesion by p-SHP2/NF-kappaB/RELT signal pathway

by | Jul 2, 2024 | Publications

J Exp Clin Cancer Res. 2024 Jul 1;43(1):183. doi: 10.1186/s13046-024-03110-y. ABSTRACT BACKGROUND: Leukocyte Ig-like receptor B family 4 (LILRB4) as an immune checkpoint on myeloid cells is a potential target for tumor therapy. Extensive osteolytic bone lesion is the...
« Older Entries
Next Entries »

Recent Content

  • Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti-CD38 Monoclonal Antibodies: A Systematic Review
  • Pharmacists Play an Essential Role in Bispecific Therapy for Multiple Myeloma
  • Implications of lymphocyte kinetics after chimeric antigen receptor T cell therapy for multiple myeloma
  • Multiple myeloma as a challenging multidimensional random process: a data-driven web-based application for treatment selection
  • Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes
  • Deep Responses in Smoldering Multiple Myeloma Linked to Improved Outcomes
  • Urine-free response criteria predict progression-free survival in multiple myeloma: a post hoc analysis of BMT CTN 0702
  • Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma
  • High WEE1 expression is independently linked to poor survival in multiple myeloma
  • Evaluation of anti-CD38 monoclonal antibody-based immunotherapy in multiple myeloma with renal insufficiency: a systematic review and meta-analysis
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT